Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | SOD1 | P00441 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128558 | 0.87 | SCN9A (0.35) | IDO1CES2SOD1RXRARXRB | |
| SCHEMBL16193422 | 0.85 | ALDH1A1 (0.44) | CES2MAPTRXRARXRBRXRG | |
| SCHEMBL2341199 | 0.85 | RAPGEF4 (0.38) | IDO1SOD1MAPTRAPGEF4 | |
| SCHEMBL16783567 | 0.85 | PTGS1 (0.39) | IDO1CES2SOD1 | |
| SCHEMBL4457498 | 0.81 | CES2 (0.41) | IDO1CES2SOD1GPR84MAPT | |
| SCHEMBL28906423 | 0.79 | IDO1 (0.34) | IDO1SOD1RXRARXRBRXRG | |
| SCHEMBL289310 | 0.78 | TSHR (0.47) | IDO1CES2ALDH1A1TSHR | |
| SCHEMBL29868638 | 0.78 | CES2 (0.39) | IDO1CES2SOD1MAPTITGB3 | |
| SCHEMBL892616 | 0.76 | CYP11B1 (0.36) | TLR8 | |
| SCHEMBL204711 | 0.75 | CA1 (0.47) | IDO1CES2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3599234-B1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INT (DE) | 2021-04-07 | — | — | EP | claimed |
| EP-3599234-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2020-01-29 | — | — | EP | claimed |
| US-10189776-B2 | Stereoselective process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-29 | — | — | US | claimed |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-13 | — | — | US | claimed |
| EP-3350173-A1 | STEREOSELECTIVE PROCESS | Boehringer Ingelheim International GmbH (DE) | 2018-07-25 | — | — | EP | claimed |
| EP-3149138-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | The Procter & Gamble Company (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2017046355-A1 | STEREOSELECTIVE PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-23 | — | — | WO | claimed |
| WO-2015184209-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | THE PROCTER & GAMBLE COMPANY (US) | 2015-12-03 | — | — | WO | claimed |
| US-20150344817-A1 | WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE | THE PROCTER & GAMBLE COMPANY | 2015-12-03 | — | — | US | claimed |
| US-8921299-B2 | Detergents having acceptable color | THE PROCTER & GAMBLE COMPANY (US) | 2014-12-30 | — | — | US | claimed |
| US-20120289707-A1 | PROCESS FOR THE PREPARATION OF AMIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-11-15 | — | — | US | claimed |
| EP-2280944-A1 | PROCESS FOR THE PREPARATION OF AMIDES | Syngenta Limited (GB) | 2011-02-09 | — | — | EP | claimed |
| WO-2009138375-A1 | PROCESS FOR THE PREPARATION OF AMIDES | SYNGENTA LIMITED (GB) | 2009-11-19 | — | — | WO | claimed |
| EP-4043500-B1 | ETHYLENE·ALPHA-OLEFIN·NON-CONJUGATED POLYENE COPOLYMER, USE THEREOF, AND MANUFACTURING METHOD THEREOF | MITSUI CHEMICALS INC (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20250243307-A1 | ETHYLENE/a-OLEFIN/5-VINYL-2-NORBORNENE COPOLYMER, COMPOSITION CONTAINING SAID COPOLYMER, AND CROSSLINKED BODY | MITSUI CHEMICALS, INC. (JP) | 2025-07-31 | — | — | US | disclosed |
| US-12319758-B2 | Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-06-03 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319758-B2 | Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers | PCNA, NIT2, MCM7 | IDO1 1175/4885CES2 1075/4885SOD1 40/4885 |
| US-10189776-B2 | Stereoselective process | CYP4A11, CYP4B1, CYP3A4 | IDO1 3137/4885CES2 491/4885SOD1 4243/4885 |
| US-20120289707-A1 | PROCESS FOR THE PREPARATION OF AMIDES | CHRM2, CHRM1, CYP1B1 | IDO1 638/4885CES2 220/4885SOD1 619/4885 |
| US-20180258031-A1 | STEREOSELECTIVE PROCESS | CYP4A11, CYP4B1, CYP3A4 | IDO1 3137/4885CES2 491/4885SOD1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.